Yesterday Companion Medical announced a deal with Senseonics to integrate Senseonics sensor data into the InPen system. Companion already has a deal with Dexcom, and we suspect at some point will also strike a deal with Abbott even though Abbott continues to invest in Bigfoot. In these days of interoperability with all the toys talking with all the other toys deals such as these are becoming commonplace.
The goal here is to get Tyler from the development stage to the market. The fact is all the technology needed for Tyler is already available. Besides Companion all the insulin companies have . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.